Home > Insider Trading > Filing (0001209191-18-034203)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1659323	Iterum Therapeutics Plc	ITRM	()	E9

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1619859	L.p. X Canaan	2765 Sand Hill Road Menlo Park CA 94025		Yes	No	Yes	No
1673228	Canaan Partners X Llc	2765 Sand Hill Road Menlo Park CA 94025		Yes	No	Yes	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Ordinary Shares	Acquisiton	2018-05-30	721,408	$0.00	721,408	No	4	C	Direct
Ordinary Shares	Acquisiton	2018-05-30	275,446	$0.00	996,854	No	4	C	Direct
Ordinary Shares	Acquisiton	2018-05-30	229,660	$0.00	1,226,514	No	4	C	Direct
Ordinary Shares	Acquisiton	2018-05-30	506,656	$13.00	1,733,170	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Series A Preferred Shares	Disposition	2018-05-30	721,408	$0.00	721,408	$0.00
Ordinary Shares	Series B-1 Preferred Shares	Disposition	2018-05-30	275,446	$0.00	275,446	$0.00
Ordinary Shares	Series B-2 Preferred Shares	Disposition	2018-05-30	229,660	$0.00	229,660	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"), and each may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund. Brenton K. Ahrens, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan X, collectively. Canaan X disclaims Section 16 beneficial ownership of the shares held by the Canaan Fund, except to the extent, if any, of its pecuniary interest therein.
The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.
The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer and had no expiration date.